Clinical Trials Logo

Acute Gouty Arthritis clinical trials

View clinical trials related to Acute Gouty Arthritis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03002974 Completed - Clinical trials for Acute Gouty Arthritis

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

anaGO
Start date: December 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how anakinra relieves pain for patients with acute gout that cannot take non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine. The patients will be divided in different treatment groups to compare anakinra to the available drug triamcinolone.

NCT ID: NCT01431638 Completed - Clinical trials for Acute Gouty Arthritis

Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Start date: August 25, 2011
Phase: Phase 3
Study type: Interventional

This is a 36 week open-label extension of the canakinumab pre-filled syringe study for safety and tolerability in patients who have frequent flares of acute gouty arthritis.

NCT ID: NCT01356602 Completed - Clinical trials for Acute Gouty Arthritis

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Start date: May 2011
Phase: Phase 3
Study type: Interventional

This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis.

NCT ID: NCT00170781 Completed - Clinical trials for Acute Gouty Arthritis

Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout

Start date: June 2005
Phase: Phase 4
Study type: Interventional

This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout. This is a multi-center, double-blind, randomized, parallel group study comparing a single daily dose of 400 mg lumiracoxib with the established dose of indomethacin 50 mg taken three times a day in terms of efficacy